Tags: superbug | drug-resistant | hospital | experimental | antibiotic | Roche | bacterial

Experimental Antibiotic Targets Drug-Resistant Superbugs

Monday, 04 Nov 2013 07:21 AM

Swiss drugmaker Roche will pay up to $548 million for an experimental antibiotic, marking a rare foray by a major pharmaceutical firm into the battle against so-called "superbug" infections found in hospitals.
 
The World Health Organization has warned of the growing public health threat from drug-resistant superbugs. There are 25,000 deaths each year in the European Union alone due to antimicrobial resistance, Roche said on Monday.
 
However, the problem is not yet widespread enough to attract major investment by most top pharmaceutical companies, with many of them in fact cutting back research into antibiotics.
Pfizer, once the leader in the field, closed its antibiotic R&D center in Connecticut in 2011, while Bristol-Myers Squibb and Eli Lilly have also cut back, leaving few big firms in the game.

Editor’s Note: 3 Secrets to Never Get Sick Again. Get Super Immunity for Only $4.95. Click here.
 
Roche said it had signed an exclusive global licensing deal to develop and commercialize privately held Polyphor's investigational antibiotic POL7080 against certain superbug infections found in hospitals.
 
Under the deal, Roche will make an upfront payment of $38 million and milestone payments of up to $510 million.
 
In addition, Polyphor will be entitled to tiered, double-digit percentage royalties on any product sales and will retain the option to co-promote an inhaled formulation of POL7080 in Europe, Roche said.
 
POL7080 belongs to a new class of antibiotics that kills Pseudomonas aeruginosa, a bacterium found in hospitals and resistant to many antibiotic treatments, by a novel mode of action, the Swiss group added.
 
It has demonstrated clinical safety and tolerance in a Phase I clinical trial and holds promise for the treatment of serious and often life-threatening bacterial infections caused by multi-drug resistant Pseudomonas species, Roche said.
 
Pseudomonas aeruginosa, which accounts for one in every 10 hospital-acquired infections in the United States, can cause death in around 50 percent of patients with weakened immune systems, such as those suffering from cancer, AIDS or chronic infections like cystic fibrosis.

Editor’s Note: 3 Secrets to Never Get Sick Again. Get Super Immunity for Only $4.95. Click here.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
Swiss drugmaker Roche will pay up to $548 million for an experimental antibiotic, marking a rare foray by a major pharmaceutical firm into the battle against so-called superbug infections found in hospitals. The World Health Organization has warned of the growing public...
superbug,drug-resistant,hospital,experimental,antibiotic,Roche,bacterial,infections
347
2013-21-04
Monday, 04 Nov 2013 07:21 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved